IL13 and Eczematoid dermatitis: However, several paradoxical cutaneous adverse effects have been demonstrated during the biological treatment for psoriasis and eczema.[4,7,8] For instance, dupilumab, targeting the IL-4 receptor alpha subunit, inhibits the IL-4 and IL-13 signaling cascades, thereby inducing the Th1 or Th17 immune-associated cutaneous diseases during in treatment of AD.[9] Similarly, Th2 immune-associated cutaneous disorders have been reported in biogical treatement of psoriasis.